Sanochemia: New contrast agent aims to detect the smallest lymphatic metastases in prostate cancer
NEUFELD, Austria, April 17, 2024 /PRNewswire/ -- Sanochemia Pharmazeutika secures exclusive licensing rights to a new MRI contrast agent based on ferumoxtran, that is in an advanced pivotal trial in clinical phase III and may be used to detect the smallest lymph node metastases in prostate cancer patients.
- NEUFELD, Austria, April 17, 2024 /PRNewswire/ -- Sanochemia Pharmazeutika secures exclusive licensing rights to a new MRI contrast agent based on ferumoxtran, that is in an advanced pivotal trial in clinical phase III and may be used to detect the smallest lymph node metastases in prostate cancer patients.
- The product, which is currently under development in late phase III at several renowned European clinics, shall carry the registered trademark Ferrotran®.
- Ferrotran® contains iron-based superparamagnetic nanoparticles and is intended to be used to detect even the smallest lymph node metastases in prostate cancer patients.
- Only recently, an agreement with b.e.imaging (Baden-Baden, Germany) was announced on the MRI contrast agent Resotran® (ferucarbotran) for the detection of focal liver lesions in adults.